novo nordisk cagrilintide presents new Phase III data for next-gen amylin Novo Nordisk shares plunge after
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters Topline data from REDEFINE 1 found CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. https: t.co JA9E3FpCsN #ObesityManagement # Cagrilintide: Mechanism, Effects & Research Studies CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine
Pay in 4 interest-free payments of $6.96 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15



